Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Regeneron Announces First Recipients of Annual "Regeneron Prize for Creative Innovation"



 Regeneron Announces First Recipients of Annual "Regeneron Prize for Creative
                                 Innovation"

New National Prize Recognizes Talented Early-Career Scientists Poised to Make
Important Contributions to Scientific Discovery

PR Newswire

TARRYTOWN, N.Y., June 27, 2013

TARRYTOWN, N.Y., June 27, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN)  today announced the first recipients of the Regeneron Prize
for Creative Innovation, a new initiative designed to acknowledge, reward, and
foster talented early-career scientists.   

"We are excited to offer the Regeneron Prize for Creative Innovation to
scientists who are beginning their research careers and show great promise,"
said George Yancopoulos, M.D., Ph.D., Founding Scientist, President, Regeneron
Laboratories, and Chief Scientific Officer, who designed the program as a way
to identify and track developing scientific talent.  "We believe this program
demonstrates the Company's commitment to supporting science education and
research excellence."

Regeneron is awarding two prizes for outstanding research this year. 

  o The Regeneron Prize for Creative Innovation by a Postdoctoral Fellow has
    been awarded to Chuan Wu, Brigham and Women's Hospital, Harvard
    University.
  o The Regeneron Prize for Creative Innovation by a Graduate Student has been
    awarded to Cody Gilleland, Massachusetts Institute of Technology.

Additionally, this year Regeneron is recognizing two graduate student
researchers with Honorable Mentions: Daria Zamolodchikov, Rockefeller
University and Lukasz Bugaj, University of California at Berkeley. 

Requests for applicants were distributed to key academic institutions around
the nation in February.  Each institution was asked to nominate two graduate
students and two postdoctoral fellows.

A key component of each application was a proposal, drafted by the nominee,
explaining a "dream" project in biomedical research.  This proposal gave the
review committee at Regeneron insights into the nominee's creativity and
ability to think independently as a scientist.  Each nominee also included a
curriculum vitae and list of publications; the trainee's productivity in his
or her current laboratory also factored into the review committee's decision.

"We're looking for productive, creative, and innovative young scientists who
are not afraid to think outside the box," said Susan Croll, Ph.D., a Regeneron
scientist who directs the postdoctoral program at Regeneron.  "The results of
their research proposal should have the potential to drive biomedicine
forward."

Ten finalists were invited to Regeneron in April to meet with scientists, give
presentations about their proposals, and tour the Company's facilities.  The
two winning trainees will each receive $50,000, and the institutions
nominating the two winners will each receive a $5,000 donation to support
their seminar series.  The remaining finalists will each be awarded $5,000,
except for the two recipients of "Honorable Mentions," who will each receive
$10,000.

"Regeneron is proud to support and encourage early career scientists as they
forge their futures in biomedicine.  To build the pipeline of promising new
treatments for unmet medical needs, we must also develop the pipeline of
talented new medical researchers," concluded Dr. Croll.

About Regeneron Pharmaceuticals
Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York, that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions. 
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition and has product candidates in development in other
areas of high unmet medical need, including hypercholesterolemia, oncology,
rheumatoid arthritis, allergic asthma, and atopic dermatitis.  The Company was
ranked by Science magazine as the top employer in the global biopharmaceutical
industry in 2012.  For additional information about the company, please visit
www.regeneron.com.

Contact Information:   
Peter Dworkin
Corporate Communications  
914.847.7640  
peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Website: http://www.regeneron.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement